Nicotine produces a brief anxiolytic feeling that's largely the relief of withdrawal between doses. Across the full day, smokers and vapers have higher rates of anxiety disorders than non-users. The pattern most patients describe as "I smoke because I'm anxious" is usually backwards: the smoking is maintaining the anxiety. Cessation produces a transient one-to-four week withdrawal-related increase in anxiety followed by sustained improvement in most former users.
The acute effect
A cigarette or vape delivers nicotine to the brain within seconds. The user feels reduced anxiety, sometimes mild euphoria, slight cognitive sharpening, and reduced craving. The effect is real, and is one of the reasons nicotine is among the most reinforcing drugs in widespread use.
What the user is largely feeling, after the first few exposures, is relief of withdrawal. The body has adapted to a baseline of nicotine. As blood levels fall between doses, withdrawal symptoms begin: anxiety, irritability, restlessness, difficulty concentrating, and craving. The next dose relieves these symptoms and is interpreted as anxiety relief.
This is why long-term smokers describe "needing" cigarettes for anxiety: between doses they experience nicotine withdrawal, which is anxious, and dosing fixes it.
The full-day picture
Across the day, smokers and vapers have higher rates of anxiety disorders than non-users. Multiple studies have shown that sustained smoking cessation is associated with reduced anxiety and depression symptoms, not increased. The CDC tobacco and mental health resources cover the broader population-level picture.
The reason is partly that nicotine maintains the anxiety it appears to relieve: each between-dose withdrawal is experienced as anxiety, and the relief from the next dose maintains the cycle. The reason is also partly that the brain adapts to the constant nicotine exposure in ways that raise baseline arousal.
The vaping concern
Vaping has changed the nicotine landscape, particularly in young adults. Vapes often deliver higher nicotine concentrations than cigarettes. The discrete dosing pattern of cigarettes (one cigarette at a time, with social and time constraints) is replaced by continuous low-level dosing throughout the day. Many young adult vapers consume more nicotine daily than they would have as smokers.
From an anxiety standpoint, this matters because:
- More frequent dosing produces more frequent inter-dose withdrawal
- Higher nicotine concentrations produce stronger physical dependence
- The early onset of use in adolescence is associated with worse anxiety outcomes
- The NIDA vaping research overview describes the broader picture
The anxiety arc during cessation
The first one to four weeks of cessation involve:
- Increased anxiety, often peaking in the first week
- Irritability
- Difficulty concentrating
- Sleep disruption
- Strong cravings, particularly in the first few days
- Sometimes a transient increase in panic attack frequency in patients with panic disorder
These symptoms peak in days one through three for most users and largely resolve by week four. After that period, most former users describe reduced baseline anxiety compared with their smoking baseline.
The withdrawal-related anxiety is sometimes interpreted as evidence that "I really do need cigarettes for anxiety." In most cases this isn't what's happening. The withdrawal is bounded; the long-term effect of cessation on anxiety is generally favorable.
Smoking cessation aids
The major evidence-based aids include:
- Nicotine replacement therapy (patch, gum, lozenge, inhaler): provides controlled nicotine without smoke or vapor; tapered over weeks to months
- Bupropion (Wellbutrin): an antidepressant also approved for smoking cessation; reduces craving and withdrawal
- Varenicline (Chantix): a partial nicotine receptor agonist; among the most effective single-agent cessation aids
Combining a behavioral support program with one of these aids roughly doubles cessation success rates. For patients with co-occurring depression or anxiety, bupropion is sometimes the preferred aid because it addresses both conditions, though bupropion can be activating and is reviewed individually for each patient.
The SAMHSA tobacco cessation resources include the national quitline (1-800-QUIT-NOW) and other free supports.
How to talk to a clinician about cessation
Most psychiatrists and primary care physicians have substantial experience with smoking cessation. A useful framing for the conversation:
- Honest disclosure of current use (cigarettes per day, vape use, other tobacco)
- Prior quit attempts and what happened
- Co-occurring anxiety, depression, or other psychiatric conditions
- Specific concerns about anxiety during cessation
- Interest in pharmacological aids
For patients with generalized anxiety disorder, starting an SSRI before a quit attempt often makes the cessation period easier to manage. For patients on existing psychiatric medications, dose adjustments are sometimes needed after cessation because smoking changes the metabolism of several medications (clozapine, olanzapine, fluvoxamine, and others through CYP1A2 induction).
Nicotine and anxiety medications
Smoking induces CYP1A2 and reduces blood levels of medications metabolized through that pathway. Quitting can produce a sudden rise in levels of these medications, sometimes producing side effects that look like the original condition worsening. Clinicians who manage psychiatric medications routinely consider this when patients quit smoking.
For the clinical encyclopedia entry on this condition, see Shrinkopedia →